Takeda’s seizure drug fails to meet primary goal in late-stage studies

(Reuters) – Japan’s Takeda said on Monday its experimental drug to treat seizure disorders failed to meet the primary endpoint in two late-stage studies.

The drug, soticlestat, was being tested in adult and pediatric patients with Dravet syndrome and Lennox-Gastaut syndrome.

These are severe forms of epilepsy characterized by frequent and prolonged seizures, which usually appear during infancy or early childhood.

Takeda plans to speak with regulatory authorities to determine next steps.

(Reporting by Mariam Sunny in Bangalore; Editing by Shailesh Kuber)